Summary
Natural killer (NK) and T subsets were analyzed with appropriate dual labeling by flow cytometry in peripheral blood (PB) (66 cases) and bone marrow (BM) (55 cases) from patients with de novo AML in order to determine: (a) their distribution at diagnosis, (b) the correlation between PB and BM in NK subpopulations, (c) their relationship with the clinical and hematological disease characteristics, and (d) the changes occurring upon achieving complete remission (CR). NK cells defined by the expression of CD56 in the absence of CD3 were significantly increased at diagnosis and their levels in PB correlated with those of BM. By contrast, NK subsets defined by CD16 expression (CD16+ CD2+ and CD16+ CD2− NK-cell subsets) as well as T lymphocytes with NK activity (CD56+ CD3+), although increased in PB, displayed normal levels in BM. An additional observation of interest was the expansion of an immature NK population lacking CD16 Ag expression (CD56+CD16−). AML cases were divided into two groups according to the absolute number of NK cells in PB; patients with the highest levels showed an increased proportion of blast cells in PB (p=0.01), monocytic subtypes (p=0.03), and expression of CD11b, CD14, and CD4 antigens (p=0.05). Infections at diagnosis were not related to the level of NK cells. In 19 patients who achieved complete remission the number of CD56+CD3− cells tended to be reduced to within the normal range. Other T-cell populations, including the CD4 naive and memory cells, were also explored, their distribution being normal in the PB of AML patients. By contrast, the cytotoxic subset CD8+/CD57+was significantly increased (p< 0.001). These data point to the existence of marked alterations of NK cells in AML patients, possibly reflecting a host-tumor immunological interaction.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adler A, Albo V, Blatt J, Whiteside TL, Herberman RB (1989) Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. II. Feasibility of LAK generation in children with active disease and in remission. Blood 74:1690–1697
Adler A, Chervenick PA, Whiteside TL, Lotzová E, Herberman RB (1988) Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71:709–716
Adler A, Chervenick P, Whiteside T, Lotzová E, Herberman RB (1987) IL-2 mediated in vitro stimulation of killer cells derived from peripheral blood (PB)/bone marrow (BM) of acute leukemia patients. Fed Proc 46:1509 (abstr 6957)
Afify ZA, Abdel-Mageed A, Findley HW, Ragab AH (1990) Cytotoxicity of purified Leu 19+ cells from the peripheral blood of children with acute lymphocytic leukemia. Cancer 66:469–473
Archimbaud E, Bailly M, Doré JF (1991) Inducibility of lymphokine-activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Br J Haematol 77:328–334
Autran B, Leblond V, Sadat-Sowti B, Lefranc E, Got P, Sutton L, Binet JL, Debre P (1991) A soluble factor release by CD8+CD57+lymphocytes from bone marrow transplanted patients inhibits cell-mediated cytolysis. Blood 77:2237–2241
Dixon WJ (1983) (Biomedical-Data Package): Statistical software. University of California, Berkeley
Foa R, Fierro MT, Cesano A, Guarini A, Bonferroni M, Raspadori D, Miniero R, Lauria F, Gavosto F (1991) Defective lymphokine-activated cell generation and activity in acute leukemia patients with active disease. Blood 78:1041–1046
Foa R, Guarini A, Gillio-Tos A, Cardona S, Fierro MT, Meloni G, Tosti S, Mandelli F, Gavosto F (1991) Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin-2: evidence of in vitro lymphokine-activated killer cell generation. Cancer Res 51:964–968
Gambacorti-Passerini C, Rivoltini L, Supino R, Mariani M, Parmiani G (1988) Differential lysis of melanoma clones by autologous recombinant interleukin-2 activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx). Int J Cancer 42:544–548
Giorgi JV, Kesson AM, Chou CC (1992) Immunodeficiency and infectious diseases. In: Rose NR, de Macario EC, Fahey JL, Freidman H, Penn GM (eds) Manual of clinical and laboratory immunology. Section D: Immune cell phenotyping by flow cytometry. Amer Soc Microbiol, Washington DC, pp 174–181
González M, San Miguel JF, Gascón A, Moro MJ, Hernández JM, Ortega F, Jiménez R, Guerras L, Romero M, Casanova F, Sanz MA, Portero JA, Orfao A (1992) Increased expression of natural killer-associated and activation antigens in multiple myeloma. Am J Hematol 39:84–89
Lanier LL, Phillips JH (1987) Evidence for three types of human cytotoxic lymphocyte. Immunol Today 7:132–135
Lanier LL, Phillips JH, Hackett J, Tutt M, Kuman V (1986) Natural killer cells: definition of a cell type rather than a function. J Immunol 137:2735–2739
Lim SH, Worman CP, Jewell A, Goldstone AH (1991) Production of tumor-derived suppressor factor in patients with acute myeloid leukemia. Leuk Res 15:263–268
Lotzová E, Savary CA, Schachnr JR, Huh JO, McCredie K (1991) Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2. Am J Hematol 37:88–99
Lotzová E, Savary CA, Totpal K, Schachner J, Lichtiger B, McCredie KB, Freireich EJ (1991) Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia. Leuk Res 15:245–254
Lotzová E, McCredie KB, Muesse L, Dicke KA, Freireich EJ (1989) Natural killer cells in man: their possible involvement in leukemia and bone marrow transplantation. In: Baum SJ, Ledney (eds) Experimental hematology today. Springer, Berlin Heidelberg New York, p 207
Lum LG, Ueda M (1992) Immunodeficiency and the role of suppressor cells after the bone marrow transplantation. Clin Immunol Immunopathol 63:103–109
Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, López M, Sainty D, Marit G, Stoppa AM, Reiffers J et al. (1991) High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 78:2182–2187
Milosevic D, Marinkovic M, Suvajdzic N, Spuzic I (1991) Determination of T lymphocyte subpopulations in malignant lymphoproliferative diseases. Glas Srp Akad Nauka [Med] 41:105–111
Nagler A, Lainer LL, Cwirla S, Phillips JH (1989) Comparative studies of human FcR III-positive and -negative natural killer cells. J Immunol 143:3183–3191
Naume B, Gately M, Espevik T (1992) A comparative study of IL-12 (cytotoxic lymphocyte maturation factor), IL-2 and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol 148:2429–2436
Palucka AK, Porwit A, Reizenstein P (1991) Resistance of leukemic blasts to lymphokine-activated killer (LAK)-mediated cytotoxicity is not related to their adhesion properties. Eur J Haematol 47:123–127
Pizzolo G, Trentin L, Vinante F, Agostini C, Zambello R, Masciarelli M, Feruglio C, Dazzi F, Todeschini G, Chilosi M, et al. (1988) Natural killer cell function and lymphoid sub-populations in acute non-lymphoblastic leukemia in complete remission. Br J Cancer 58:368–372
Pollack SB (1983) In vivo functions of natural killer cells. Surv Synth Pathol Res 2:93–98
Rees RC (1990) MHC restricted and non-restricted killer lymphocytes. Blood Rev 4:204–210
Richards SJ, Scott CS (1992) Human NK cells in health and disease: clinical, functional, phenotypic and DNA genotypic characteristics. Leukemia Lymphoma 7:377–399
Robertson MJ, Ritz J (1990) Biology and clinical relevance of human natural killer cells. Blood 76:2421–2438
Rosenberg SA, Lotze MT, Mull LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson GN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897
San Miguel JF, Caballero MD, González M (1985) T-cell sub-populations in patients with monoclonal gammopathies: essential monoclonal gammopathy, multiple myeloma and Waldeström's macroglobulinemia. Am J Haematol 20:267–273
San Miguel JF, Hernández JM, González-Sarmiento R, Gonzalez M, Sánchez I, Orfao A, Cañizo MC, Lápez-Borrasca A (1991) Acute leukemia after primary myelodisplastic syndrome: immunophenotyping, genotypic and clinical characteristics. Blood 78:768–774
San Miguel JF, Ojeda E, González M, Orfao A, Cañizo MC, Sánchez I, López-Borrassca A (1989) Prognostic value of immunological markers in acute myeloblastic leukemia. Leukemia 3:108–111
Savary CA, Lotzová E (1989) Natural killer cell-mediated inhibition of growth myeloid and lymphoid clonogenic leukemias. Exp Hematol 17:183–187
Sorskaar D, Forre O, Tjonneland S, Lie SO (1988) Altered natural killer cell activity in childhood acute non-lymphoid leukaemia. Augmented natural killer activity and cells expressing the Leu 7 and Leu 11b (CD16) markers in the bone marrow of children in remission. Scand J Immunol 28:11–17
Tratkiewicz JA, Szer J, Boyd RL (1988) Are lymphokine-activated killer cells a possible form of leukemia immunotherapy? Adv Exp Med Biol 237:447–450
Tratkiewicz JA, Szer J (1990) Loss of natural killer activity as an indicator of relapse in acute leukemia. Clin Exp Immunol 80:241–246
Tratkiewicz JA, Szer J, Boyd RL (1990) Lymphokine activated killer cytotoxicity against leukaemic blast cells. Clin Exp Immunol 80:94–99
Trentin L, Pizzolo G, Ferugio C, Zambello R, Masciarelli M, Bulian P, Agostini C, Vinante F, Zanotti R, Semenzato G (1989) Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. Cancer 64:667–672
Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA (1992) The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 10:33–40
Yamada S, Komiyama A (1991) Decrease in number of CD16 (Leu 11)+CD45RA(2h4)+cells and defective production of natural killer cytotoxic factor in childhood acute lymphoblastic leukemia. Leuk Res 15:785–790
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vidriales, M.B., Orfao, A., López- Berges, M.C. et al. Lymphoid subsets in acute myeloid leukemias: Increased number of cells with NK phenotype and normal T-cell distribution. Ann Hematol 67, 217–222 (1993). https://doi.org/10.1007/BF01715050
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01715050